Cargando…

SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.

SR 4233 (3-amino-1,2,4-benzotriazine 1,4-dioxide, WIN 59075, tirapazamine) is the lead compound in a new class of bioreductive anticancer drugs, the benzotriazine di-N-oxides. It is currently undergoing Phase I clinical testing. The preferential tumour cell killing of SR 4233 is a result of its high...

Descripción completa

Detalles Bibliográficos
Autor principal:	Brown, J. M.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 1993
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1968495/ https://www.ncbi.nlm.nih.gov/pubmed/8512801

Ejemplares similares

The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.
por: Lartigau, E., et al.
Publicado: (1996)

Importance of P450 reductase activity in determining sensitivity of breast tumour cells to the bioreductive drug, tirapazamine (SR 4233).
por: Patterson, A. V., et al.
Publicado: (1995)

Exploiting tumour hypoxia and overcoming mutant p53 with tirapazamine.
por: Brown, J. M.
Publicado: (1998)

Molecular mechanisms of tirapazamine (SR 4233, Win 59075)-induced hepatocyte toxicity under low oxygen concentrations.
por: Khan, S., et al.
Publicado: (1995)

Does reductive metabolism predict response to tirapazamine (SR 4233) in human non-small-cell lung cancer cell lines?
por: Chinje, E C, et al.
Publicado: (1999)

Metabolism of the bioreductive cytotoxin SR 4233 by tumour cells: enzymatic studies.
por: Wang, J., et al.
Publicado: (1993)

Overexpression of human NADPH:cytochrome c (P450) reductase confers enhanced sensitivity to both tirapazamine (SR 4233) and RSU 1069.
por: Patterson, A. V., et al.
Publicado: (1997)

Enhancement of the cytotoxicity of SR 4233 to normal and malignant tissues by hypoxic breathing.
por: Minchinton, A. I., et al.
Publicado: (1992)

NADPH:cytochrome c (P450) reductase activates tirapazamine (SR4233) to restore hypoxic and oxic cytotoxicity in an aerobic resistant derivative of the A549 lung cancer cell line
por: Saunders, M P, et al.
Publicado: (2000)

SR 4233 cytotoxicity and metabolism in DNA repair-competent and repair-deficient cell cultures.
por: Biedermann, K. A., et al.
Publicado: (1991)

The effect of pH on the aerobic and hypoxic cytotoxicity of SR4233 in HT-29 cells.
por: Skarsgard, L. D., et al.
Publicado: (1993)

Molecular mechanisms of SR 4233-induced hepatocyte toxicity under aerobic versus hypoxic conditions.
por: Silva, J. M., et al.
Publicado: (1993)

Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin
por: Kovacs, M S, et al.
Publicado: (1999)

Detection of hypoxia by measurement of DNA damage in individual cells from spheroids and murine tumours exposed to bioreductive drugs. I. Tirapazamine.
por: Olive, P. L.
Publicado: (1995)

Tirapazamine-cisplatin: the synergy.
por: Gatzemeier, U., et al.
Publicado: (1998)

The effects of three bioreductive drugs (mitomycin C, RSU-1069 and SR4233) on cell lines selected for their sensitivity to mitomycin C or ionising radiation.
por: Keohane, A., et al.
Publicado: (1990)

Enhancement of the anti-tumour effect of cyclophosphamide by the bioreductive drugs AQ4N and tirapazamine
por: Friery, O P, et al.
Publicado: (2000)

Improving Tirapazamine (TPZ) to Target and Eradicate Hypoxia Tumors by Gold Nanoparticle Carriers
por: Ajnai, Giimel, et al.
Publicado: (2022)

Phase I Trial on Arterial Embolization with Hypoxia Activated Tirapazamine for Unresectable Hepatocellular Carcinoma
por: Abi-Jaoudeh, Nadine, et al.
Publicado: (2021)

Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro.
por: Siim, B. G., et al.
Publicado: (1996)

Polydopamine-coated UiO-66 nanoparticles loaded with perfluorotributylamine/tirapazamine for hypoxia-activated osteosarcoma therapy
por: Chen, Hongfang, et al.
Publicado: (2021)

Electronic structure and reactivity of tirapazamine as a radiosensitizer
por: Romero, José, et al.
Publicado: (2021)

Applicability of Combination with Tirapazamine in Boron Neutron Capture Therapy
por: Masunaga, Shin‐ichiro, et al.
Publicado: (1998)

Development and Validation of a Kilogram-Scale Synthesis of Tirapazamine
por: Lienard, Philippe, et al.
Publicado: (2020)

Effects of Bioreductive Agents, Tirapazamine and Mitomycin C, on Quiescent Cell Populations in Solid Tumors, Evaluated by Micronucleus Assay
por: Masunaga, Shin‐ichiro, et al.
Publicado: (1997)

Changes in the Sensitivity of Intratumor Cells during Fractionated Tirapazamine Administration
por: Masunaga, Shin‐ichiro, et al.
Publicado: (2000)

Redox Proteomic Profile of Tirapazamine-Resistant Murine Hepatoma Cells
por: Nemeikaitė-Čėnienė, Aušra, et al.
Publicado: (2023)

Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development
por: Feng, Jie, et al.
Publicado: (2019)

Subcellular Location of Tirapazamine Reduction Dramatically Affects Aerobic but Not Anoxic Cytotoxicity
por: Guise, Chris P., et al.
Publicado: (2020)

Kinetics of Flavoenzyme-Catalyzed Reduction of Tirapazamine Derivatives: Implications for Their Prooxidant Cytotoxicity
por: Nemeikaitė-Čėnienė, Aušra, et al.
Publicado: (2019)

Pharmacomicrobiomics: exploiting the drug-microbiota interactions in anticancer therapies
por: Panebianco, Concetta, et al.
Publicado: (2018)

Ring-Selective Fragmentation in the Tirapazamine Molecule upon Low-Energy Electron Attachment
por: Arthur-Baidoo, Eugene, et al.
Publicado: (2021)

Tirapazamine-Doxorubicin Interaction Referring to Heart Oxidative Stress and Ca(2+) Balance Protein Levels
por: Sliwinska, Justyna, et al.
Publicado: (2012)

Reactions in Tirapazamine Induced by the Attachment of Low‐Energy Electrons: Dissociation Versus Roaming of OH
por: Arthur‐Baidoo, Eugene, et al.
Publicado: (2020)

The Development of Nonthermal Plasma and Tirapazamine as a Novel Combination Therapy to Treat Melanoma In Situ
por: Yehl, Matthew, et al.
Publicado: (2023)

Bioreductive drugs and the selective induction of tumour hypoxia.
por: Bremner, J. C., et al.
Publicado: (1990)

Tirapazamine-loaded CalliSpheres microspheres: Preparation and characterization as a chemoembolization agent for liver cancer
por: Zhang, Xin, et al.
Publicado: (2023)

Development of [(131)I]I-EOE-TPZ and [(131)I]I-EOE-TPZMO: Novel Tirapazamine (TPZ)-Based Radioiodinated Pharmaceuticals for Application in Theranostic Management of Hypoxia
por: Elsaidi, Hassan, et al.
Publicado: (2019)

The emergence of drug resistance in tumours: a characteristic which may be exploited therapeutically.
por: Tattersall, M. H.
Publicado: (1973)

Toward Hypoxia-Selective DNA-Alkylating Agents Built by Grafting Nitrogen Mustards onto the Bioreductively Activated, Hypoxia-Selective DNA-Oxidizing Agent 3-Amino-1,2,4-benzotriazine 1,4-Dioxide (Tirapazamine)
por: Johnson, Kevin M., et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_2ekg27a5l69n1u6paa7jjnn4k3